drugset / Trial / NCT04144335
N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV
RandomizedSequentialOpen-labelTreatment
Summary
To assess the safety of combination immune therapy in HIV-infected participants whose HIV is controlled with ART, by determining the incidence and severity of adverse events.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | PGT121 | Monoclonal antibody | — | — |
| Subject | VRC07-523LS | Monoclonal antibody | — | — |
| Subject | haNK™ Cells | Unknown | 2e+09 cells | Intravenous |